Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study

Leuk Lymphoma. 2015;56(11):3227-9. doi: 10.3109/10428194.2015.1028055. Epub 2015 Mar 31.

Authors

Susanne Schreiber¹, Alexander Hoellein¹, Thomas Decker², Stefanie Jilg¹, Martin Dreyling³, Christian Peschel¹, Ulrich Keller¹

Affiliations

¹ a III. Medical Department, Technische Universität München , Munich , Germany.
² b Onkologie Ravensburg , Ravensburg , Germany.
³ c Medical Department III , Ludwig-Maximilians-Universität München , Munich , Germany.

PMID: 25754578
DOI: 10.3109/10428194.2015.1028055

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Everolimus / administration & dosage
Everolimus / adverse effects
Everolimus / therapeutic use*
Humans
Lymphoma, Mantle-Cell / drug therapy*
Lymphoma, Mantle-Cell / mortality
Lymphoma, Mantle-Cell / pathology
Maintenance Chemotherapy
Treatment Outcome

Substances

Antineoplastic Agents
Everolimus